Keros Therapeutics Inc’s recent filing unveils that its Director GORDON CARL L unloaded Company’s shares for reported $11.0 million on Aug 13 ’24. In the deal valued at $44.01 per share,250,000 shares were sold. As a result of this transaction, GORDON CARL L now holds 119,522 shares worth roughly $7.15 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, ORBIMED ADVISORS LLC sold 250,000 shares, generating $11,002,500 in total proceeds. Upon selling the shares at $44.01, the Director now owns 119,522 shares.
Before that, OrbiMed Genesis Master Fund, L bought 29,400 shares. Keros Therapeutics Inc shares valued at $1,318,296 were divested by the Shareholder at a price of $44.84 per share.
Guggenheim initiated its Keros Therapeutics Inc [KROS] rating to a Buy in a research note published on September 23, 2024; the price target was $96. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in late June with a ‘”an Outperform”‘ rating. William Blair began covering KROS with “an Outperform” recommendation on February 21, 2024. Wells Fargo started covering the stock on December 08, 2023. It rated KROS as “an Overweight”.
Price Performance Review of KROS
On Tuesday, Keros Therapeutics Inc [NASDAQ:KROS] saw its stock jump 2.96% to $59.79. Over the last five days, the stock has gained 7.56%. Keros Therapeutics Inc shares have risen nearly 50.38% since the year began. Nevertheless, the stocks have risen 87.55% over the past one year. While a 52-week high of $73.00 was reached on 02/29/24, a 52-week low of $27.02 was recorded on 01/02/24. SMA at 50 days reached $50.62, while 200 days put it at $53.13.
Levels Of Support And Resistance For KROS Stock
The 24-hour chart illustrates a support level at 58.05, which if violated will result in even more drops to 56.32. On the upside, there is a resistance level at 60.72. A further resistance level may holdings at 61.66. The Relative Strength Index (RSI) on the 14-day chart is 70.02, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.63, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 2.07%. Stochastics %K at 77.76% indicates the stock is a holding.
How much short interest is there in Keros Therapeutics Inc?
A steep rise in short interest was recorded in Keros Therapeutics Inc stocks on 2024-09-13, growing by 11163.0 shares to a total of 3.5 million shares. Yahoo Finance data shows the prior-month short interest on 2024-08-15 was 3.49 million shares. There was a rise of 0.32%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on July 31, 2023 when Wedbush began covering the stock and recommended ‘”an Outperform”‘ rating along with a $86 price target.
